Summary of opinion: BTVPUR, 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 12:27
Summary of opinion: BTVPUR, 21/05/2026 Positive
Human medicines European public assessment report (EPAR): Jubereq, denosumab, Date of authorisation: 26/05/2025, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 22 May 2026 - 12:25
Human medicines European public assessment report (EPAR): Jubereq, denosumab, Date of authorisation: 26/05/2025, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Date of authorisation: 26/05/2025, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 22 May 2026 - 12:18
Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Date of authorisation: 26/05/2025, Revision: 2, Status: Authorised
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2026
Submitted by Anonymous (not verified) on 22 May 2026 - 11:50
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2026
Summary of opinion: Braftovi, 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:37
Summary of opinion: Braftovi, 21/05/2026 Positive
Summary of opinion: Iclusig, 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:36
Summary of opinion: Iclusig, 21/05/2026 Positive
Summary of opinion: Tepkinly, 21/05/2026 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:36
Summary of opinion: Tepkinly, 21/05/2026 Positive
Human medicines European public assessment report (EPAR): Colchicine Agepha Pharma, colchicine, Status: Opinion
Submitted by Anonymous (not verified) on 22 May 2026 - 11:35
Human medicines European public assessment report (EPAR): Colchicine Agepha Pharma, colchicine, Status: Opinion
Orphan designation: bevacizumab Treatment of hereditary haemorrhagic telangiectasia, 16/12/2014 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:32
Orphan designation: bevacizumab Treatment of hereditary haemorrhagic telangiectasia, 16/12/2014 Positive
Orphan designation: alpelisib Treatment of PIK3CA related overgrowth spectrum, 26/03/2021 Positive
Submitted by Anonymous (not verified) on 22 May 2026 - 11:32
Orphan designation: alpelisib Treatment of PIK3CA related overgrowth spectrum, 26/03/2021 Positive